News | March 12, 2015

Study Reveals How Dietary Phosphate Can Increase Heart Disease Risk

Findings are especially relevant for patients with kidney disease, who lose the ability to excrete phosphate

March 12, 2015 — A new study has found that high phosphate levels can cause a stress signal inside the cells that line blood vessels, leading to the release of microparticles that promote the formation of blood clots. The findings, which appear in an upcoming issue of the Journal of the American Society of Nephrology (JASN), provide new insights into how phosphate in the diet can impact heart health.

Inorganic phosphate is a nutrient in nearly all diets. Because patients with chronic kidney disease (CKD) lose the ability to excrete excess phosphate in their urine, the nutrient accumulates in their blood and cells. Such “hyperphosphatemia” is thought to be an important contributor to CKD patients’ increased risk of cardiovascular disease.

To investigate this link, a team led by Alan Bevington, BA, D.P.hil, and Ph.D. student Nima Abbasian, BSc, MSc, University of Leicester, UK, examined the effects of hyperphosphatemia on the cells that form the lining of blood vessels. The researchers’ experiments revealed a mechanism by which an excess of inorganic phosphate—similar to levels found in the blood of CKD patients—causes a stress signal inside these cells. In cells that are stressed in this way, fragments known as microparticles break off from the cells and can promote the formation of blood clots. “This is important because blocking of blood vessels by blood clots—a process known as thrombosis—is a common cause of injury and death, occurring in a wide range of human illnesses including CKD,” said Bevington.

While the effects described in this study are especially relevant to patients with kidney dysfunction who lose the ability to excrete excess phosphate in their urine, nearly all modern Western diets are rich in phosphate, so even healthy individuals with normally functioning kidneys may experience some elevation of blood phosphate levels. In addition, there are a number of metabolic disturbances that can raise phosphate levels inside cells. “It’s possible therefore that the results of this study will also be relevant in other situations in addition to CKD,” said Abbasian.

For more information: www.asn-online.org

Related Content

Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | FFR Catheters| August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
Ra Medical Systems Granted Broad Patent for DABRA Catheter
News | Peripheral Artery Disease (PAD)| August 09, 2017
August 9, 2017 — Ra Medical Systems announced that the United States Patent and Trademark Office (USPTO) has granted
Overlay Init